Genetic testing in long QT syndrome and clinical care

Long QT syndrome (LQTS) is an inherited electrical disorder in which delayed ventricular repolarisation can create a substrate for torsades de pointes, syncope and sudden cardiac death. Genetic testing can clarify the cause, support family screening and refine treatment, but a laboratory report is never a substitute for clinical assessment. The central task is to interpret a variant alongside the patient’s electrocardiogram, symptoms, family history and exposure to provoking factors.

Variant classification is also dynamic. A result reported as a variant of uncertain significance (VUS) may be reclassified as evidence accumulates, while a pathogenic or likely pathogenic finding may have different implications according to the affected gene and the person’s phenotype. Careful interpretation therefore requires collaboration between inherited arrhythmia specialists, clinical geneticists, genetic counsellors and diagnostic laboratories.

Australian practice adds practical considerations. Referral pathways differ between states and territories, testing may involve public hospital genetic services or private laboratories, and access can be less predictable for people living in regional and remote communities. NATA-accredited laboratory testing, culturally safe counselling and a clear plan for communicating results are essential parts of responsible care.

When genetic testing is clinically appropriate

Testing is most useful when the clinical diagnosis is plausible or established. A prolonged corrected QT interval on repeated 12-lead ECGs, unexplained exertional or startle-related syncope, documented torsades de pointes, or a compelling family history can all justify referral. The Schwartz score remains a practical framework, although QT duration must be interpreted carefully because heart rate, medications, electrolyte abnormalities and measurement technique can distort the picture.

A normal resting ECG does not exclude disease. QT prolongation can be intermittent, and some carriers have a concealed phenotype. Exercise testing, standing manoeuvres and serial ECGs may reveal abnormal repolarisation patterns in selected patients. Conversely, a borderline QTc in a person taking a QT-prolonging drug should not automatically trigger a label of inherited LQTS.

Testing should begin with an affected individual whenever possible. Identifying a familial pathogenic variant enables targeted cascade testing, which is generally more efficient and easier to interpret than broad testing in unaffected relatives. Pre-test counselling should explain possible outcomes, limitations, implications for relatives and the possibility of incidental findings, particularly when a broad arrhythmia or cardiomyopathy panel is used.

How laboratories classify variants

Most laboratories use the ACMG/AMP framework, adapted where disease-specific evidence is available. Classification considers population frequency, computational predictions, segregation in families, de novo occurrence, functional studies, the gene-disease relationship and the variant’s location or mechanism. The five familiar categories are pathogenic, likely pathogenic, uncertain significance, likely benign and benign.

For LQTS, gene-specific interpretation is important. KCNQ1, KCNH2 and SCN5A account for most genetically confirmed cases, but their mechanisms and phenotype associations differ. A missense variant in a functionally important region of KCNQ1 may carry different weight from a similarly rare change in another gene. Loss-of-function variants are well established in some genes, whereas many missense changes require stronger supporting evidence before they can be considered clinically actionable.

Population databases help exclude variants that are too common to cause a rare dominant disorder with substantial penetrance, but absence from a database is weak evidence by itself. Computational tools can support a classification but rarely settle it. Functional assays are valuable when they are validated, disease-relevant and reproducible; an isolated in-vitro result should not outweigh a well-characterised clinical phenotype or robust family data.

Interpreting a result with the phenotype

A pathogenic or likely pathogenic variant in a recognised LQTS gene can establish a molecular diagnosis, particularly when the ECG and history are compatible. It can also identify relatives who need surveillance even if they have never fainted or had a prolonged QTc. Phenotypic variability is common, so an apparently well carrier still needs an individualised risk assessment.

The genotype can inform, rather than dictate, management. KCNQ1-associated disease is often triggered by exercise, especially swimming, while KCNH2-related events may be associated with sudden auditory stimuli. SCN5A-related LQTS may show a less typical repolarisation pattern and overlap with other electrical phenotypes. These associations are useful for counselling, but they should not replace direct assessment of the patient’s triggers and ECG.

A VUS should not be used to diagnose LQTS, implant a defibrillator or restrict relatives from sport without supporting clinical evidence. Relatives should not undergo predictive testing for a VUS as though it were a pathogenic familial mutation. Instead, relatives may require clinical screening based on the pedigree and phenotype, with the family’s variant periodically reviewed for reclassification.

An apparently negative panel also needs careful explanation. It does not exclude LQTS because current testing may miss deep intronic changes, structural variants, mosaicism or disease caused by genes not yet established. A negative result should not override a convincing phenotype. The patient may still benefit from trigger avoidance, medication review, specialist follow-up and clinical assessment of relatives.

From molecular evidence to risk management

Treatment decisions rest on the probability of a malignant ventricular arrhythmia. Previous cardiac arrest, documented torsades, arrhythmic syncope, marked QT prolongation and the pattern of events within the family all matter. A genotype can strengthen diagnostic confidence, but there is no single variant result that automatically determines implantable cardioverter-defibrillator therapy.

Beta-blockers remain central for many patients, with nadolol and propranolol commonly favoured in specialist practice because of their effectiveness across important LQTS genotypes. Adherence and dose are crucial, particularly in adolescents whose weight and activity change quickly. Patients should receive a current list of medicines that may prolong the QT interval, and clinicians should correct hypokalaemia, hypomagnesaemia and other reversible contributors.

An ICD is generally considered after resuscitated cardiac arrest or recurrent arrhythmic events despite appropriate treatment, with the balance of benefit and device complications reviewed carefully. Left cardiac sympathetic denervation may be considered for selected high-risk patients who cannot tolerate beta-blockers, experience events despite therapy or have contraindications to an ICD. Decisions should be made in an inherited arrhythmia service rather than from the genetic report alone.

Risk assessment also needs to account for coexisting illness. For perspective, the discussion of sudden death risk markers in end-stage renal disease illustrates why ECG findings must be interpreted within the broader clinical context, including renal function, electrolyte shifts and competing causes of arrhythmia.

Cascade testing and Australian practice

Once a familial pathogenic variant is confirmed, first-degree relatives can usually have targeted testing after genetic counselling. A positive result supports ECG surveillance and specialist review; a negative result for the known familial variant generally avoids repeated inherited-risk investigations, although the family history and symptoms still need to be considered. Testing children requires attention to developmental stage, consent, assent and the practical consequences of labelling an asymptomatic person.

In Australia, families may enter care through a cardiologist, paediatrician, emergency department or a state-based clinical genetics service. Public genetics clinics can have waiting lists, while private testing may involve out-of-pocket costs and variable funding arrangements. A referral to an inherited arrhythmia clinic in Melbourne, Sydney, Brisbane, Perth, Adelaide or another major centre may be difficult for families in the Northern Territory, regional Queensland or rural Western Australia, making telehealth and coordinated local ECG access valuable.

Genetic counselling should address privacy, insurance and employment concerns without overstating legal protections. It should also be culturally safe. For Aboriginal and Torres Strait Islander families, clinicians should allow time for community, kinship and communication preferences, and should avoid assuming that a standard Western family-history model captures all relevant relationships. Plain-language explanations and interpreters may be needed for culturally and linguistically diverse households.

Laboratories and clinicians should document the exact variant, transcript, genome build, evidence supporting classification and the date of interpretation. Results should be reviewed when the laboratory issues an update, when a relative develops a new phenotype or when improved evidence changes the classification. A registry or family letter can help relatives navigate testing across different Australian health services.

Special situations and shared decisions

Pregnancy, postpartum care and competitive sport require coordinated planning. Beta-blocker treatment may need adjustment and obstetric, cardiology and neonatal teams should know the diagnosis. The postpartum period can be particularly important for some genotypes, while fever, vomiting, diarrhoea and medication changes can increase risk through electrolyte disturbance. Patients should receive an emergency plan that explains when urgent assessment is required.

Medication reconciliation is essential in emergency and perioperative settings. Common drugs used for infection, nausea, psychiatric illness and anaesthesia can affect repolarisation, and risk rises when several factors combine. Specialist resources such as the CredibleMeds database can support prescribing, but local protocols and an ECG should guide decisions in a high-risk patient.

Genetic information may also intersect with other arrhythmia diagnoses. A patient with aortic stenosis and atrial fibrillation, for example, may need a separate discussion of procedural and rhythm outcomes; the review of TAVR and SAVR arrhythmia impact shows why structural heart disease should not be folded into an inherited channelopathy assessment without distinction.

Shared decision-making should make uncertainty explicit. Patients need to understand what the test can answer, what it cannot answer, and how results may affect relatives. The best plan combines evidence-based risk reduction with the person’s age, occupation, sporting goals, pregnancy plans, device preferences and capacity to attend follow-up.

Clinicians working with suspected or confirmed LQTS can strengthen care by documenting phenotype and family history before ordering a panel, using an accredited laboratory, and arranging post-test counselling. Researchers and trainees can follow emerging gene-specific evidence through peer-reviewed electrophysiology literature and specialist society guidance. Access to reliable case reports, reviews and original research through the Journal of Arrhythmia can support consistent interpretation as variant science and clinical practice continue to develop.